International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.

Awan FT, Addison D, Alfraih F, Baratta SJ, Campos RN, Cugliari MS, Goh YT, Ionin VA, Mundnich S, Sverdlov AL, Tam C, Ysebaert L

Open source

DOI: 10.1182/bloodadvances.2022007938
Published: 2022 Sep 27
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2022007938,
  title = {International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.},
  author = {Awan FT and Addison D and Alfraih F and Baratta SJ and Campos RN and Cugliari MS and Goh YT and Ionin VA and Mundnich S and Sverdlov AL and Tam C and Ysebaert L},
  year = {2022},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2022007938},
  url = {https://doi.org/10.1182/bloodadvances.2022007938}
}

RIS

TY  - JOUR
TI  - International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.
AU  - Awan FT
AU  - Addison D
AU  - Alfraih F
AU  - Baratta SJ
AU  - Campos RN
AU  - Cugliari MS
AU  - Goh YT
AU  - Ionin VA
AU  - Mundnich S
AU  - Sverdlov AL
AU  - Tam C
AU  - Ysebaert L
PY  - 2022
JO  - Blood advances
DO  - 10.1182/bloodadvances.2022007938
UR  - https://doi.org/10.1182/bloodadvances.2022007938
ER  -

APA

FT, A., D, A., F, A., SJ, B., RN, C., MS, C., YT, G., VA, I., S, M., AL, S., C, T., & L, Y. (2022). International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.. Blood advances. https://doi.org/10.1182/bloodadvances.2022007938

Source records

pubmed · retrieved 2026-09-26T23:04:00.766Z